Olgram is a biotechnology company developing first-in-class, proprietary immunotherapies to treat immune deficiencies, beginning with immuno-depression after traumatic brain injury and concussion." title="" class="btn" data-container="body" data-html="true" data-id="191842" data-placement="top" data-toggle="popover" data-trigger="focus" style="color:#0077b5" tabindex="0" data-original-title="Olgram"> 869
Activities
Entity types
Location
Le Forum 2, 218 Av. Marie Curie, 74160 Archamps, France
Archamps
France
Employees
Scale: 11-50
Estimated: 5
SIREN
879302552Engaged catalyst
5Added in Motherbase
2 years, 1 month agomarine-inspired molecules to fight immunological diseases
Olgram is a biotechnology company developing first-in-class, proprietary immunotherapies to treat immune deficiencies, beginning with immuno-depression after traumatic brain injury and concussion.
Biotechnologie, immunologie, antibiorésistance, and commotions
marine-inspired molecules to fight immunological diseases
Olgram is a biotechnology company developing first-in-class, proprietary immunotherapies to treat immune deficiencies, beginning with immuno-depression after traumatic brain injury and concussion.
Catalyst | Type | Tweets | Articles | |
---|---|---|---|---|
![]() | SAVOIE-ANGELS - Investissement de proximité | Other 24 Feb 2025 | | |
![]() Auvergne-Rhone-Alpes Entreprises - Isère National and local authorities, Business Consulting and Services | Auvergne-Rhone-Alpes Entreprises - Isère National and local authorities, Business Consulting and Services | Other 27 Sep 2024 | | |
![]() ArchParc Startup accelerator & VC | ArchParc Startup accelerator & VC | Other 30 Sep 2024 | | |
![]() MEDICALPS Business Consulting and Services | MEDICALPS Business Consulting and Services | Other 16 Apr 2024 | | |
![]() Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 31 Jul 2024 | |